Due to RSG’s safety concerns and its failure in AD clinical trials, there is a lack of information on its ability to modulate BDNF in this disease; however, the recent research conducted by Sarathal and colleagues highlights the potential of targeting BDNF and delivering drugs like RSG in nanoparticle formulations in future AD clinical trials. Here, BDNF is linked to Alzheimer disease.